| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6489329 | J AND J CONSUMER INC | Pharmaceutical compositions for the treatment of rhinitis |
Apr, 2016
(8 years ago) | |
| US6469009 | J AND J CONSUMER INC | Pharmaceutical compositions for the treatment of rhinitis |
Jul, 2019
(4 years ago) | |
| US7226614 | J AND J CONSUMER INC | Tablet comprising cetirizine and pseudoephedrine |
Jun, 2022
(1 year, 10 months ago) | |
| US7014867 | J AND J CONSUMER INC | Tablet comprising cetirizine and pseudoephedrine |
Jun, 2022
(1 year, 10 months ago) | |
Zyrtec-D 12 Hour is owned by J And J Consumer Inc.
Zyrtec-D 12 Hour contains Cetirizine Hydrochloride; Pseudoephedrine Hydrochloride.
Zyrtec-D 12 Hour has a total of 4 drug patents out of which 4 drug patents have expired.
Expired drug patents of Zyrtec-D 12 Hour are:
- US6489329
- US6469009
- US7226614
- US7014867
Zyrtec-D 12 Hour was authorised for market use on 09 November, 2007.
Zyrtec-D 12 Hour is available in tablet, extended release;oral dosage forms.
Zyrtec-D 12 Hour can be used as treatment of seasonal and perennial allergic rhinitis symptoms.
The generics of Zyrtec-D 12 Hour are possible to be released after 10 June, 2022.
Drugs and Companies using CETIRIZINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE ingredient
Market Authorisation Date: 09 November, 2007
Treatment: Treatment of seasonal and perennial allergic rhinitis symptoms
Dosage: TABLET, EXTENDED RELEASE;ORAL
ZYRTEC-D 12 HOUR family patents
